Navigation Links
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
Date:3/31/2009

ing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague
  • A third generation rPA anthrax vaccine.

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities L
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  Kannalife Sciences, Inc. ("Kannalife") announces that Dr. ... Board to assist the Company in the advancement of ... cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy ... conducting the full autopsy of Mike Webster , ... Pittsburgh Steelers. It was through his examination of ...
(Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
(Date:3/4/2015)... , March 4, 2015  ECR Booth #317/Expo ... ) is showcasing a full spectrum of X-ray imaging ... quality, reduce costs, and enable greater patient throughput for ... imaging systems.  These solutions are on display at the ... Vienna, Austria this week.   ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3
... 2011 Argos Therapeutics, Inc. today announced that its late ... awarded the Nobel Prize in medicine for the discovery of ... Dr. Steinman,s discovery of dendritic cells and his research ... in adaptive immunity have led to the development of Argos, ...
... Today, Children,s Hospital at Scott & White , the ... facility between Dallas and Austin, opened its doors to patients. ... state-of-the-art Simulation Center for a mock transport of "patients" from ... White Hospital-Temple, before moving patients to the new Children,s Hospital ...
Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2Children's Hospital at Scott & White Opens 2Children's Hospital at Scott & White Opens 3Children's Hospital at Scott & White Opens 4
(Date:3/4/2015)... (PRWEB) March 04, 2015 RapidScale, a ... in Las Vegas, Nevada, on March 16th-18th. They are ... will have some of its top engineering executives in ... in the RapidScale solution set. Attendees include William Hiatt, ... Cloud Engineer; and Ryan Turpin, Cloud Support Manager. ...
(Date:3/4/2015)... SIGVARIS proved innovative when they ... compression therapy collection designed exclusively for men. Building ... is proud to announce the launch of three additional ... from a unique, extremely fine synthetic fiber, MIDTOWN MICROFIBER ... and thigh-highs offer a tailored look that is perfect ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... discussion leaders for its upcoming fifth annual Advanced ... Paris, France. The event this year will feature ... than 20 of the field’s leading companies and ... together top executives and clinical researchers from the ...
(Date:3/4/2015)... Jeannie Mai, TV personality, fashion maven, and co-host of ... the print publication. Mai embraces the overall theme of the ... clothes and personal care products. In an exclusive interview, Olympic ... an organic diet. She mentions, “Having an organic lifestyle has ... also now as I’m a full time student at New ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 i2i ... been selected by Chase Brexton Health Care, a ... today. , Chase Brexton provides comprehensive primary care, ... 30,000 patients across seven clinics in the greater ... of electronic medical records, the organization has always ...
Breaking Medicine News(10 mins):Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3
... eating dietary fiber specifically from fruits and cereals lowers ... // a connection between higher intake of fiber and ... actually looked at the dietary fiber from different sources ... study researchers analyzed several studies to determine whether the ...
... , medication errors that occur in pediatric intensive care units ... ,Researchers studied more than 11,800 children who were admitted into ... errors. They defined an error as any preventable event that ... medical errors were reported during the course of the study. ...
... A new study shows weight gain after age 18 can ... women who // are not taking hormone replacement therapy. ... to 74, by asking them about their weight at age ... been periodically asked to provide updates on their weight, in ...
... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
... a recent study conducted researchers suggest that kids who ... having their tonsils and adenoids out. ,Adenotonsillectomy is ... of the time, it is performed to treat recurring ... have also used the surgery to treat obstructive sleep ...
... strikes men between 20 and 34 years old. Advances ... improved survival rate from the cancer, but since men ... the effect of the cancer and its treatment on ... treatment reduces fertility, others have found fertility rates unchanged. ...
Cached Medicine News:
...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
...
Tips are sharp on both sides to puncture, cut and tear the capsule...
Medicine Products: